Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
05 November 2024 | Story Leonie Bolleurs | Photo Supplied
BOOTES-6 telescope station
The BOOTES-6 telescope station captured a South African sighting of the southern lights, a rare atmospheric phenomenon powered by solar activity.

The northern lights, with their vibrant displays of green, pink, and violet hues, have become a famous attraction in Nordic countries. But in early October, a rare sighting of the southern lights – or aurora australis – was reported in South Africa, surprising many.

Prof Pieter Meintjes, Professor in the Department of Physics at the University of the Free State (UFS), explains that both the northern and southern lights are the result of charged particles from coronal mass ejections (CMEs) on the sun, which are captured by Earth’s magnetic field. "The interaction between magnetic fields and charged particles, such as protons and electrons, is very interesting. The magnetic field forces these particles to spiral around the field lines, ultimately guiding them towards the magnetic poles. As these particles enter Earth’s atmosphere, they collide with atmospheric atoms, causing a beautiful glow. The colours of the aurora indicate which atoms are involved. Typically, hydrogen shines red, while oxygen and nitrogen produce a greenish-blue tinge," he says.

Observing the southern lights

When the display occurs above the northern magnetic pole, it is called the aurora borealis (northern lights) and can typically be observed over regions such as Alaska, Greenland, and the Nordic countries. Above the southern magnetic pole, it is known as aurora australis (southern lights), usually visible over places such as Antarctica and New Zealand. “In extreme cases – when gigantic mass ejections occurred – it can also be observed in mid-latitudes such as South Africa,” says Prof Meintjes.

This recent and rare South African sighting was also captured by the BOOTES-6 telescope station at Boyden Observatory, located just outside Bloemfontein. According to Prof Meintjes, the telescope station has an all-sky monitor – a camera constantly watching the sky for changes and monitoring, among others, cloud cover to ensure that the telescope is always safe from weather. While the monitor was taking photos of the night sky, Prof Alberto Castro-Tirado, a research professor at the Institute of Astrophysics of Andalusia in Spain, picked up the aurora.

The Institute of Astrophysics of Andalusia in Spain, in collaboration with the University College Dublin (UCD), is partnering with the UFS in a research-driven initiative involving the BOOTES-6 telescope station, installed in 2022 during the COVID-19 pandemic. Under a Memorandum of Understanding that was recently renewed for another five years, the UFS and UCD share approximately 30% of the telescope's observing time dedicated to UFS research.

“The DPRT telescope (Dolores Pérez-Ramírez telescope), named after a Spanish astronomer and lecturer at the University of Jaén, contributes significantly to our research, with publications resulting from contributions made by the telescope station and collaborators on gamma-ray bursts, occultations, and transient events co-authored by me and a colleague in the department, Dr Hendrik van Heerden,” notes Prof Meintjes.

Research-driven initiatives

Data from the telescope station is also used for their in-house projects and contributes significantly to the work of their PhD students that will be submitted in the next few years. This includes the PhD work of Helene Szegedi, who uses data from the BOOTES-6 telescope station to study cataclysmic variable systems – compact binaries that erupt regularly. Another PhD student, Joleen Barnard, studies blazar variability under the guidance of Prof Brian van Soelen. Blazars, explains Prof Meintjes, are the core of distant galaxies powered by supermassive black holes. These cosmic jets are pointed towards Earth, but fortunately, they are millions or billions of light years away; otherwise, their impact would be devastating to life on Earth.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept